Our Translational Research
“We are very happy to consolidate a portion of our external research activities that are currently being outsourced to several different contract research organizations as this we believe will shorten development timeline. Moreover we are pleased to have found a partner that shares our business model approach”
- Dr. Frédéric Cren, Head of Research at Solvay Pharmaceuticals
See more:
Viriom and Roche select ChemDiv to Develop HIV Program 
ChemDiv and Avineuro Pharmaceuticals Announce Successful Milestones Reached
Our Clinical Development
"I want to thank you for the level of service, attention and expertise … shown to this project. We appreciate attentiveness, guidance and oversight of the Project and our PI's. Thank you and the team for partnering with Antigenics"
- Jay Vanderbilt, Llt.D., Director, Development Operations and Resources, Antigenics
Our Pre-clinical Development
“This collaboration for finding novel molecules to treat tuberculosis reflects perfect complementarities between top-level expertise of ChemDiv and our disease-based approach for High Content Screening,”
- Dr. Thierry Christophe, Head of Screening Technologies and Pharmacology of Institute Pasteur Korea.
See more:
ChemDiv and iDialog nominate novel inhibitor of Hepatitis C for clinical development
Our Drug Discovery
"Our new agreement reflects the success of our previous relationship and our high esteem for the quality of ChemDiv’s discovery and synthesis capabilities…ChemDiv will continue to complement our in-house activities to add further novelty to Merck’s discovery projects.”
- Dr. Peter Raddatz, Vice President of Medicinal Chemistry at Merck KGaA
“We are delighted to be able to work with ChemDiv, as this collaboration combines the complementary skills of both companies to create new compounds to our innovative targets for infections disease. We are very optimistic and happy to having found such a capable partner in ChemDiv.”
Dr. Motoyuki Yajima, Executive Managing Director of Research and Development of Kaken Pharmaceuticals
“We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality discovery capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline"
- Dr. Teo Uysal, President and CEO, Syndexa Pharmaceuticals
"Our business relationship with ChemDiv is entering a phase of joint scientific endeavours with ambitious goals of innovation. …Useful new chemical entities are generated and tested with an efficiency level of the highest standard"
- Francesco Colotta, VP of Oncology , NervianoMS
“We are excited to initiate this collaborative discovery project with ChemDiv. The project has an excellent chance of success, based on ChemDiv’s excellent track record in small molecule drug discovery.”
- Kevin L. Moore, M.D., President Siwa Biotech Corporation
See more:
ChemDiv - Lilly Collaboration Expanded To Include New Discovery Program
ChemDiv Reaches Milestone with Nerviano Medical Sciences
Our Discovery Tools Chemistry
“We are pleased to be working with ChemDiv on this important medicinal chemistry effort to optimize SOS pathway inhibitors discovered by Achaogen.”
Dr. Heinz Moser, Achaogen’s Senior Vice President for Chemistry. We selected ChemDiv for their ability to consistently execute complex chemistry and deliver quality results … the company has earned an excellent reputation in our small molecule discovery programs”.
- Dr. Ofir Moreno, Senior Director of Chemistry, Dendreon
|
Testimonials
